INCYIncyte Corp.
$103.73
$0.74
(0.71%)
Closed $104.40
$0.6675
(0.64%)
After Hours
EarningsJul 28
Mkt Cap$20.71B
Vol1.67M
Incyte's Minjuvi Approved In Japan For Relapsed Or Refractory DLBCL
(RTTNews) - Incyte Biosciences (INCY) in Japan announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL...
Nasdaq News: Markets
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Zacks
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Zacks
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (12 years of age) with...
Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs...
Business Wire
Results from Incytes Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide...
Business Wire
Here's Why Incyte (INCY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
Zacks
<
1
2
...
>